A QSAR study to predict the survival motor neuron promoter activity of candidate diaminoquinazoline derivatives for the potential treatment of spinal muscular atrophy

References

• G.E. Opera, S. Kröber, M.L. McWhorter, W. Rossoll, S. Müller, M. Krawczak, G.J. Bassell, C.E. Beattie, and B. Wirth, Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy, Science 320 (2008), pp. 524–527. doi:10.1126/science.1155085.
   PubMedGoogle Scholar
• R.S. Anderton and F.L. Mastaglia, Advances and challenges in developing a therapy for spinal muscular atrophy, Expert Rev. Neurother. 15 (2015), pp. 895–908. doi:10.1586/14737175.2015.1059757.
   PubMed Web of Science ®Google Scholar
• C. Madocsai, S.R. Lim, T. Geib, B.J. Lam, and K.J. Hertel, Correction of SMN2 pre-mRNA splicing by antisense U7 small nuclear RNAs, Mol. Ther. 12 (2005), pp. 1013–1022. doi:10.1016/j.ymthe.2005.08.022.
   PubMed Web of Science ®Google Scholar
• S. Lefebvre, L. Bürglen, S. Reboullet, O. Clermont, P. Burlet, L. Viollet, B. Benichou, C. Cruaud, P. Millasseau, M. Zeviani, D.L. Paslier, J. Frezal, D. Cohen, J. Weissenbach, A. Munnich, and J. Melki, Identification and characterization of a spinal muscular atrophy-determining gene, Cell 80 (1995), pp. 155–165. doi:10.1016/0092-8674(95)90460-3.
   PubMed Web of Science ®Google Scholar
• M.D. Howell, N.N. Singh, and R.N. Singh, Advances in therapeutic development for spinal muscular atrophy, Future Med. Chem. 6 (2014), pp. 1081–1099. doi:10.4155/fmc.14.63.
   PubMed Web of Science ®Google Scholar
• C.F. Rochette, N. Gilbert, and L.R. Simard, SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens, Hum. Genet. 108 (2001), pp. 255–266. doi:10.1007/s004390100473.
   PubMed Web of Science ®Google Scholar
• M. Calucho, S. Bernal, L. Alías, F. March, A. Venceslá, F.J. Rodríguez-Álvarez, E. Aller, R.M. Fernández, S. Borrego, J.M. Millán, C. Hernández-Chico, I. Cuscó, P. Fuentes-Prior, and E.F. Tizzano, Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2,834 reported cases, Neuromuscular Disord. 28 (2018), pp. 208–215. doi:10.1016/j.nmd.2018.01.003.
   PubMed Web of Science ®Google Scholar
• D.C. Schorling, A. Pechmann, and J. Kirschner, Advances in treatment of spinal muscular atrophy, Neuromuscular Disord. 7 (2020), pp. 1–13. doi:10.3233/JND-190424.
   Google Scholar
• J. Thurmond, M.E.R. Butchbach, M. Palomo, B. Pease, M. Rao, L. Bedell, M. Pai, G. Keyvan, R. Mishra, M. Haraldsson, T. Andresson, G. Bragason, M. Thosteinsdottir, J.M. Bjornsson, D.D. Coovert, A.H.M. Burghes, M.E. Gurney, and J. Singh, Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of SMA, Med. Chem. 51 (2008), pp. 449–469. doi:10.1021/jm061475p.
   Google Scholar
• F. Farooq, S. Balabanian, X. Liu, M. Holcik, and A. MacKenzie, p38 mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR, Hum. Mol. Genet. 18 (2009), pp. 4035–4045. doi:10.1093/hmg/ddp352.
   PubMedGoogle Scholar
• M.A. Waldrop and S.J. Kolb, Current treatment options in neurology-SMA therapeutics, Curr. Treat. Options Neurol. 21 (2019), pp. 1–11. doi:10.1007/s11940-019-0568-z.
   PubMedGoogle Scholar
• A.N. Calder, E.J. Androphy, and K.J. Hodgetts, Small molecules in development for the treatment of spinal muscular atrophy, Med. Chem. 59 (2016), pp. 10067–10083. doi:10.1021/acs.jmedchem.6b00670.
   Google Scholar
• J. Jarecki, X. Chen, A. Bernardino, D.D. Coovert, M. Whitney, A. Burghes, J. Stack, and B.A. Pollok, Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: Early leads towards a therapeutic for spinal muscular atrophy, Hum. Mol. Genet. 14 (2005), pp. 2003–2018. doi:10.1093/hmg/ddi205.
   PubMed Web of Science ®Google Scholar
• J.P. Van Meerbeke, R.M. Gibbs, H.L. Plasterer, W. Miao, Z. Feng, M.Y. Lin, and C.J. Sumner, The DcpS inhibitor RG3039 improves motor function in SMA mice, Hum. Mol. Genet. 22 (2013), pp. 4074–4083. doi:10.1093/hmg/ddt257.
   PubMed Web of Science ®Google Scholar
• J. Singh, M. Salcius, S.W. Liu, B.L. Staker, R. Mishra, J. Thurmond, G. Michaud, D.R. Mattoon, J. Printen, and J. Christensen, DcpS as a therapeutic target for spinal muscular atrophy, ACS Chem. Biol. 3 (2008), pp. 711–722. doi:10.1021/cb800120t.
   PubMed Web of Science ®Google Scholar
• L.C. Chong, G. Gandhi, J.M. Lee, W.W.Y. Yeo, and S.B. Choi, Drug discovery of spinal muscular atrophy (SMA) from the computational perspective: A comprehensive review, Int. J. Mol. Sci. 22 (2021), pp. 8962. doi:10.3390/ijms22168962.
   PubMedGoogle Scholar
• L. Zhang, J. Tan, D. Han, and H. Zhu, From machine learning to deep learning: Progress in machine intelligence for rational drug discovery, Drug Discov. Today 22 (2017), pp. 1680–1685. doi:10.1016/j.drudis.2017.08.010.
   PubMed Web of Science ®Google Scholar
• W. Li, How do SMA-linked mutations of SMN1 lead to structural/functional deficiency of the SMA protein?, PLoS ONE 12 (2017), pp. e0178519. doi:10.1371/journal.pone.0178519.
   PubMedGoogle Scholar
• J.D. Zhang, L. Sach-Peltason, C. Kramer, K. Wang, and M. Ebeling, Multiscale modelling of drug mechanism and safety, Drug Discov. Today 25 (2020), pp. 519–534. doi:10.1016/j.drudis.2019.12.009.
   PubMedGoogle Scholar
• R. Duranay, R. Bashirov, and A. Şeytanoğlu, Simulation-based identification of optimal combination of drug candidates for spinal muscular atrophy, Procedia Comput. Sci. 120 (2017), pp. 253–259. doi:10.1016/j.procs.2017.11.236.
   Google Scholar
• A. Garcia-Lopez, F. Tessaro, H.R.A. Jonker, A. Wacker, C. Richter, A. Comte, N. Berntenis, R. Schmucki, K. Hatje, O. Petermann, G. Chiriano, R. Perozzo, D. Sciarra, P. Konieczny, I. Faustino, G. Fournet, M. Orozco, R. Artero, F. Metzger, M. Ebeling, P. Goekjian, B. Joseph, H. Schwalbe, and L. Scapozza, Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes, Nat. Commun. 9 (2018), pp. 1–12. doi:10.1038/s41467-018-04110-1.
   PubMedGoogle Scholar
• J. Axford, M.J. Sung, J. Manchester, D. Chin, M. Jain, Y. Shin, I. Dix, L.G. Hamann, A.K. Cheung, R. Sivasankaran, K. Briner, N.A. Dales, and B. Hurley, Use of intramolecular 1,5-sulfur−oxygen and 1,5-sulfur−halogen interactions in the design of n‑methyl-5-aryl‑n‑(2,2 6,6-tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine SMN2 splicing modulators, Med. Chem. 64 (2021), pp. 4744–4761. doi:10.1021/acs.jmedchem.0c02173.
   Google Scholar
• SPARTAN 16, Wavefunction, Inc, Irvine, USA, 2016; software available at http://wavefun.com.
   Google Scholar
• J.J.P. Stewart, Optimization of parameters for semiempirical methods V: Modification of NDDO approximations and application to 70 elements, Mol. Model. 13 (2007), pp. 1173–1213. doi:10.1007/s00894-007-0233-4.
   PubMed Web of Science ®Google Scholar
• Y. Zhao and D.G. Truhlar, The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: Two new functionals and systematic testing of four M06-class functionals and 12 other functionals, Theor. Chem. Acc. 120 (2008), pp. 215–241.
   Web of Science ®Google Scholar
• A.A. Kaya, E. Salamci, A. Menzek, S.S. Erdem, E. Şahin, and K. Ecer, Reaction of 9-oxabicyclo[4.2.1]non-7-ene-1-ol with tetrazine: An unusually facile intramolecular rearrangement, Tetrahedron 73 (2017), pp. 5381–5388. doi:10.1016/j.tet.2017.07.040.
   Google Scholar
• C. Dokuzparmak, F.O. Tuncay, S.B. Ozdemir, B. Kurnaz, I. Demir, A. Colak, S.S. Erdem, and N. Yildirim, Newly synthesized piperazine derivatives as tyrosinase inhibitors: In vitro and in silico studies, Iran. Chem. Soc. 19 (2022), pp. 2739–2748. doi:10.1007/s13738-021-02487-3.
   Google Scholar
• U. Cakmak, F.O. Tuncay, S.B. Ozdemir, E.A. Demir, İ. Demir, A. Colak, S.C. Uzuner, S.S. Erdem, and N. Yildirim, Synthesis of hydrazine containing piperazine or benzimidazole derivatives and their potential as α-amylase inhibitors by molecular docking, inhibition kinetics and in vitro cytotoxicity activity studies, Med. Chem. Res. 30 (2021), pp. 1886–1904. doi:10.1007/s00044-021-02785-8.
   Google Scholar
• H. Dulger, O. Sari, N. Demirel, and S.S. Erdem, Computational insight into the enantioselectivity of homoboroproline catalyzed asymmetric aldol reaction, ChemistrySelect 4 (2019), pp. 7959–7967. doi:10.1002/slct.201901737.
   Google Scholar
• Y. Du, O. Sari, S.S. Erdem, and A. Whiting, A bifunctional B,N-Based asymmetric catalytic nitrostyrene-Michael addition acting through a 10-membered ring cyclic transition state, Helv. Chim. Acta 104 (2021), pp. e202100199. doi:10.1002/hlca.202100199.
   Google Scholar
• Kode srl, Dragon (software for molecular descriptor calculation) version 7.0.2, 2016; software available at https://chm.kode-solutions.net.
   Google Scholar
• P. Gramatica, N. Chirico, E. Papa, S. Cassani, and S. Kovarich, QSARINS: A new software for the development, analysis, and validation of QSAR MLR models, Comput. Chem. Software news and updates 34 (2013), pp. 2121–2132. doi:10.1002/jcc.23361.
   Google Scholar
• P. Gramatica, S. Cassani, and N. Chirico, QSARINS-chem: Insubria datasets and new QSAR/QSPR models for environmental pollutants in QSARINS, Comput. Chem. Software news and updates 35 (2014), pp. 1036–1044. doi:10.1002/jcc.23576.
   Google Scholar
• QSARINS 2.2.1., 2015; software available at www.qsar.it.
   Google Scholar
• R. Todeschini, V. Consonni, and A. Maiocchi, The K correlation index: Theory development and its application in chemometrics, Chemom. Int. Lab. Syst. 46 (1999), pp. 13–29. doi:10.1016/S0169-7439(98)00124-5.
   Web of Science ®Google Scholar
• L.M. Shi, H. Fang, W. Tong, J. Wu, R. Perkins, R.M. Blair, W.S. Branham, S.L. Dial, C.L. Moland, and D.M. Sheehan, QSAR models using a large diverse set of estrogens, Chem. Inf. Comput. Sci. 41 (2001), pp. 186–195. doi:10.1021/ci000066d.
   PubMedGoogle Scholar
• G. Schüürmann, R. Ebert, J. Chen, B. Wang, and R. Kühne, External validation and prediction employing the predictive squared correlation coefficients test set activity mean vs training set activity mean, Chem. Inf. Model. 48 (2008), pp. 2140–2145. doi:10.1021/ci800253u.
   PubMed Web of Science ®Google Scholar
• V. Consonni, D. Ballabio, and R. Todeschini, Comments on definition of Q2 parameter for QSAR validation, Chem. Inf. Model. 49 (2009), pp. 1669–1678. doi:10.1021/ci900115y.
   PubMed Web of Science ®Google Scholar
• V. Consonni, D. Ballabio, and R. Todeschini, Evaluation of model predictive ability by external validation techniques, Chemom. 24 (2010), pp. 194–201. doi:10.1002/cem.1290.
   Web of Science ®Google Scholar
• L.I. Lin, A concordance correlation coefficient to evaluate reproducibility, Biometrics 31 (1989), pp. 255–268. doi:10.2307/2532051.
   Google Scholar
• L.I. Lin, Assay validation using the concordance correlation coefficient, Biometrics 48 (1992), pp. 599–604. doi:10.2307/2532314.
   Web of Science ®Google Scholar
• N. Chirico and P. Gramatica, Real external predictivity of QSAR models: How to evaluate it? Comparison of different validation criteria and proposal of using the concordance correlation coefficient, Chem. Inf. Model. 51 (2011), pp. 2320–2335. doi:10.1021/ci200211n.
   PubMed Web of Science ®Google Scholar
• N. Chirico and P. Gramatica, Real external predictivity of QSAR models. Part 2. New inter-comparable thresholds for different validation criteria and the need for scatter plot inspection, Chem. Inf. Model. 52 (2012), pp. 2044–2058. doi:10.1021/ci300084j.
   PubMed Web of Science ®Google Scholar
• P.K. Ojha, I. Mitra, R.N. Das, and K. Roy, Further exploring r2m metrics for validation of QSPR models, Chemom. Intell. Lab. Syst. 107 (2011), pp. 194–205. doi:10.1016/j.chemolab.2011.03.011.
   Web of Science ®Google Scholar
• A. Golbraikh and A. Tropsha, Beware of q2!, Mol. Graph. Model. 20 (2002), pp. 269–276. doi:10.1016/S1093-3263(01)00123-1.
   PubMed Web of Science ®Google Scholar
• OECD, Guidance document on the validation of (quantitative) structure–activity relationship [(Q)SAR] models, ENV/JM/MONO (2007)2, OECD Environment Health and Safety Publications Series of Testing and Assessment No. 69, Organisation for Economic Co-operation and Development, Paris, 2007.
   Google Scholar
• P. Gramatica, S. Cassani, P.P. Roy, S. Kovarich, C.W. Yap, and E. Papa, QSAR modeling is not “Push a button and find a correlation”: A case study of toxicity of(Benzo-)triazoles on algae, Mol. Inform. 31 (2012), pp. 817–835. doi:10.1002/minf.201200075.
   PubMed Web of Science ®Google Scholar
• K. Roy, P. Ambure, and S. Kar, On a simple approach for determining applicability domain of QSAR models, Chemom. Int. Lab. Syst. 145 (2015), pp. 22–29. doi:10.1016/j.chemolab.2015.04.013.
   Web of Science ®Google Scholar
• K. Roy, R.N. Das, P. Ambure, and R.B. Aher, Be aware of error measures, further studies on validation of predictive QSAR models, Chemom. Int. Lab. Syst. 152 (2016), pp. 18–33. doi:10.1016/j.chemolab.2016.01.008.
   Web of Science ®Google Scholar
• A. Rietz, H. Li, K.M. Quist, J.J. Cherry, C.L. Lorson, B.G. Burnett, and K.J. Hodgetts, Discovery of a small molecule probe that post-translationally stabilizes the survival motor neuron protein for the treatment of spinal muscular atrophy, Med. Chem. 60 (2017), pp. 4594–4610. doi:10.1021/acs.jmedchem.6b01885.
   Google Scholar
• K. Roy, P. Ambure, and S. Kar, How precise are our quantitative structure activity relationship derived predictions for new query chemicals?, ACS Omega 3 (2018), pp. 11392–11406. doi:10.1021/acsomega.8b01647.
   PubMed Web of Science ®Google Scholar
• P. Erzincan, M.T. Saçan, B.Y. Dursun, Ö. Danış, S. Demir, S.S. Erdem, and A. Ogan, QSAR models for antioxidant activity of new coumarin derivatives, SAR QSAR Environ. Res. 26 (2015), pp. 721–737. doi:10.1080/1062936X.2015.1088571.
   PubMed Web of Science ®Google Scholar